Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer with prior taxane exposure

Autor:	Lance C. Pagliaro, Pauline Dieringer, Nizar M. Tannir, Paul Mathew, Alan J. Rodney, E. Jonasch
Rok vydání:	2005
Předmět:	Oncology Cancer Research medicine.medical_specialty Taxane business.industry Phases of clinical research medicine.disease Gemcitabine Capecitabine Prostate cancer Androgen independent prostate cancer Internal medicine Medicine business medicine.drug
Zdroj:	Journal of Clinical Oncology. 23:4750-4750
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2005.23.16_suppl.4750
Popis:	4750 Background: Single-agent response rates of 12% and 7% have been reported for capecitabine and gemcitabine, respectively, in androgen-independent prostate cancer (AIPCa). The primary objective ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::dc7a12a1c6cde08dd2a9f0e79e201b56 https://doi.org/10.1200/jco.2005.23.16_suppl.4750 Zobrazit plný text záznamu